Latest Conference Articles

Addressing the external factors that can have an impact on patient health can make clinical interventions more effective when administered.

The tools that can be used to reduce health disparities exist, but they must be widely disseminated to populations across the US.

Pharmacists can fill a role for patients, but without technology supporting workflows and reimbursement efforts, challenges will remain.

Through Surescripts, pharmacists can cut down on back-and-forth with prescribers’ offices, saving valuable time for patient care.

Pharmacists must be able to view clinical information about patients in order to provide the best clinical care.

However, reimbursement for these services for pharmacists remains a crucial issue.

Inviting members of Congress into the pharmacy helps legislators experience first hand the value that pharmacists bring to their communities.

Bipartisan support—in a polarized Congress—underscores the importance of pharmacy benefit manager reform.

A collaboration with Blue Cross and Blue Shield of North Carolina focused on commercial populations has improved care and lowered costs in the state.

Both the restructuring of direct and indirect remuneration fees and health care cyber attacks made an impact on the industry in the first half of 2024.

Perhaps unsurprisingly, GLP-1 therapies are expected to continue making headlines within the industry.

To scale up diabetes intervention programs, sustainable workflows, trainings, and payment models are key.

Pharmacists need support—through partnerships and reimbursement—to provide more diverse services to patients.

Sustainable health care models require buy-in from multiple stakeholders, including pharmacists, payers, and patients.

Sustainable pharmacy partnerships require addressing financial, technology, and customer needs.

As clinical research continues, investigators are learning more about how GLP-1 drugs modify cardiovascular risks.

Lifestyle changes—including eating fruits, vegetables, and whole grains—can help patients, especially those with diabetes or hypertension, improve outcomes.

Sharing concrete steps and suggestions can help ease the way for patients looking to transition to a more healthful lifestyle.

Health care professionals all agree that a healthy diet is the foundation of cardiovascular and cardiometabolic health, but follow-through on the population level is lacking.

GLP-1 therapies are being evaluated to treat cardiovascular and kidney diseases in individuals with overweight or obesity.

These therapies are highly beneficial, but can come with a host of gastrointestinal adverse effects that patients may not be prepared to manage alone.

Some patients may have difficulty managing the gastrointestinal adverse effects associated with GLP-1 therapies.

Losing even 5% of body weight can improve comorbid conditions and other health complications for individuals with overweight and obesity.

Look back at some of the amazing insights during McKesson ideaShare, the premier event for community pharmacists.

Chris Cella, RPh, vice president of RxOwnership at McKesson, talks about how independent pharmacies can help improve their bottom line.

McKesson’s private brand of OTC health and wellness products are a great way for independent pharmacies to increase profits.

Emily Flaugher, Vice President and General Manager of Health Mart Atlas and Atlas Specialty at McKesson, sat down with Drug Topics to discuss McKesson solutions that help independent pharmacists maximize reimbursement.

Three posters presented at the American Diabetes Association 84th Scientific Sessions examined GLP-1 use and cardiovascular disease risk in several different patient populations.

Three posters presented at the American Diabetes Association 84th Scientific Sessions looked into the current landscape of GLP-1s.

Research presented at the American Diabetes Association 84th Scientific Sessions suggests a population approach to CGM use could be beneficial.